With $20.7 Million Series A Cash, RaNA Seeks To Be A Groundbreaker In Long Non-Coding RNA Therapeutics
By
Joseph Haas / Email the Author / “The Pink Sheet” DAILY Jan. 18, 2012
Word Count: 1137 / Article # 14120118008
Executive Summary
Biotech hopes to begin IND-enabling studies in 2013 and bring first candidate into the clinic in 2014 in a new field it believes will have applicability in numerous therapeutic areas.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.